NVAX
Price
$12.75
Change
+$1.74 (+15.80%)
Updated
Oct 9 closing price
Capitalization
1.78B
27 days until earnings call
Intraday BUY SELL Signals
PCVX
Price
$71.36
Change
+$6.35 (+9.77%)
Updated
Oct 9, 04:59 PM (EDT)
Capitalization
8.67B
31 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NVAX vs PCVX

NVAX vs PCVX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NVAX vs. PCVX commentary
Oct 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a StrongBuy and PCVX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
NVAX vs PCVX: Fundamental Ratings
NVAX
PCVX
OUTLOOK RATING
1..100
9031
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
10072
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3839
P/E GROWTH RATING
1..100
1336
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCVX's Valuation (67) in the null industry is in the same range as NVAX (75) in the Biotechnology industry. This means that PCVX’s stock grew similarly to NVAX’s over the last 12 months.

PCVX's Profit vs Risk Rating (72) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that PCVX’s stock grew similarly to NVAX’s over the last 12 months.

PCVX's SMR Rating (96) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that PCVX’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (38) in the Biotechnology industry is in the same range as PCVX (39) in the null industry. This means that NVAX’s stock grew similarly to PCVX’s over the last 12 months.

NVAX's P/E Growth Rating (13) in the Biotechnology industry is in the same range as PCVX (36) in the null industry. This means that NVAX’s stock grew similarly to PCVX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXPCVX
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 24 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
76%
COMPARISON
Comparison
Oct 10, 2026
Stock price -- (NVAX: $11.01 vs. PCVX: $65.01)
Brand notoriety: NVAX: Notable vs. PCVX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 108% vs. PCVX: 202%
Market capitalization -- NVAX: $1.78B vs. PCVX: $8.67B
NVAX [@Biotechnology] is valued at $1.78B. PCVX’s [@Biotechnology] market capitalization is $8.67B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 1 FA rating(s) are green while PCVX’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 1 green, 4 red.
  • PCVX’s FA Score: 0 green, 5 red.
According to our system of comparison, both NVAX and PCVX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 6 TA indicator(s) are bullish while PCVX’s TA Score has 6 bullish TA indicator(s).

  • NVAX’s TA Score: 6 bullish, 3 bearish.
  • PCVX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than PCVX.

Price Growth

NVAX (@Biotechnology) experienced а +3.87% price change this week, while PCVX (@Biotechnology) price change was +15.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.53%. For the same industry, the average monthly price growth was -13.44%, and the average quarterly price growth was -4.28%.

Reported Earning Dates

NVAX is expected to report earnings on Nov 05, 2026.

PCVX is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-2.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NVAX
Daily Signal:
Gain/Loss:
PCVX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ERX112.686.09
+5.71%
Direxion Daily Energy Bull 2X ETF (ERX)
PCN10.760.12
+1.13%
PIMCO Corporate & Income Strategy Fund
DANA24.97N/A
N/A
Dana Limited Volatility ETF (DANA)
ENZL44.41-0.07
-0.16%
iShares MSCI New Zealand ETF (ENZL)
XLU41.07-0.08
-0.19%
State Street Utilities Select Sector SPDR ETF (XLU)

PCVX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with BCYC. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then BCYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCVX
1D Price
Change %
PCVX100%
-2.90%
BCYC - PCVX
56%
Loosely correlated
+2.14%
VIR - PCVX
44%
Loosely correlated
-3.47%
ABUS - PCVX
43%
Loosely correlated
-2.56%
NVAX - PCVX
42%
Loosely correlated
-1.87%
CLDX - PCVX
42%
Loosely correlated
-3.71%
More